Charcot–Marie–Tooth Disease (CMT) Archives

Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics

Acquisitions, Analysts, Business, Charcot–Marie–Tooth Disease (CMT), Depression, Essential Tremor, Major Depressive Disorder (MDD), Milestone Payments, Neurological Disorders, Postpartum Depression, Potential Blockbusters, Product Pipeline, Shares, U.S. Centers for Disease Control and Prevention

Biogen will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders.

November 27, 2020/by Reuters Health

Acceleron Abandons Charcot-Marie-Tooth Program After Trial Failure

Business, Charcot–Marie–Tooth Disease (CMT), Clinical Trials, Dental, Erythroid maturation agents, Hematology, Neurological Disorders, Peripheral Nerves, R&D

Cambridge, Massachusetts-based Acceleron Pharma announced that the company’s Phase II clinical trial of ACE-083 in patients with Charcot-Marie-Tooth disease (CMT) failed to show functional improvement.

March 10, 2020/by BioSpace